SyntekaBio

SyntekaBio Share Buybacks

The Share Buybacks of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 262.00 M KRW. In the previous year, Share Buybacks was 12.00 M KRW — a change of 2,083.33% (higher).

Share Buybacks

262.00 MKRW

YoY

2,083.33%

Last updated:

Share Buybacks of SyntekaBio is 2024 262.00 M KRW. Share Buybacks of SyntekaBio was 2023 12.00 M KRW. It decreases by 2,083.33% higher compared to the previous year.

The SyntekaBio Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2018
406.74 M KRW
Jan 1, 2019
38.99 B KRW
Jan 1, 2020
1.66 B KRW
Jan 1, 2021
414.15 M KRW
Jan 1, 2022
174.13 M KRW
Jan 1, 2023
12.00 M KRW
Jan 1, 2024
262.00 M KRW
The SyntekaBio Share Buybacks history
YEARShare BuybacksYoY
262.00 MKRW+2,083.33%
12.00 MKRW-93.11%
174.13 MKRW-57.95%
414.15 MKRW-75.01%
1.66 BKRW-95.75%
38.99 BKRW+9,484.96%
406.74 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Share Buybacks of SyntekaBio is 262.00 M KRW in 2024.

Share Buybacks of SyntekaBio changed from 12.00 M KRW to 262.00 M KRW, representing a 2,083.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SyntekaBio

All Key Metrics — SyntekaBio